sglt2%3a1型糖尿病治疗新靶点

《sglt2%3a1型糖尿病治疗新靶点》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153128中国图书分类号R589.1HebeiMedicalUniversity硕士学位论文专业学位SGLT2:1型糖尿病治疗新靶点研究生:刘瑞红导师:王绵教授专业:内科学二级学院:河北医科大学第二医院2018年3月目录中文摘要···················································································1英文摘要···································································

2、················2综述SGLT2:1型糖尿病治疗新靶点··············································3致谢·························································································19个人简历···················································································20中文摘要SGLT2:1型糖尿病治疗新靶点摘要钠-葡

3、萄糖协同转运蛋白2(SGLT2)抑制剂是一类新型口服降糖药物，其通过抑制葡萄糖在肾近曲小管的重吸收，增加尿糖排出来降低血糖水平。近年来研究表明，SGLT2抑制剂作为胰岛素补充药物治疗1型糖尿病，不仅可以降低血糖、减少胰岛素用量、减轻体重，还可能有一定的心血管、肾脏潜在保护作用。同时，其也有导致酮症酸中毒、低血糖、泌尿生殖器感染发生的可能。本文将重点综述SGLT2抑制剂在联合胰岛素治疗1型糖尿病中的有效性和安全性。关键词:1型糖尿病,钠-葡萄糖协同转运蛋白2,钠-葡萄糖协同转运蛋白2抑制剂,降糖药,研究进展1英文摘要SGLT2:anewtargetforthetreatme

4、ntoftype1diabetesABSTRACTSodium-glucosecotransporter2(SGLT2)inhibitorsarethenewestclassoforalanti-diabeticmedications.ThemechanismofactionofSGLT2inhibitorsisthatSGLT2inhibitorscanmodulaterenalglucosereabsorptionandplasmaglucoselevel.Basedoncurrentstudies,SGLT2inhibitorsareeffectiveasadjun

5、cttherapytoinsulininT1DM,maynotonlyimproveglycemiccontrol,reducetotaldailyinsulindoseandbodyweight,butalsohavepotentialcardiovascularandrenalprotectiveeffects.Theirsideeffectsincludediabeticketoacidosis,hypoglycemia,urinarytractinfectionandgenitalinfection.Thispaperreviewedtheefficacyandsa

6、fetyofSGLT2inhibitors.Keywords:Type1diabetes,Sodium-glucosecotransporter2,Sodium-glucosecotransporter2inhibitors,Anti-hyperglycemia,Researchprogress2综述SGLT2:1型糖尿病治疗新靶点糖尿病是一个世界范围内的公共卫生问题，其患病率、病死率及整体损失仅次于心血管病、肿瘤，在慢性非传染性疾病中高居第3位[1]，给人类健康和生存带来巨大危害。1型糖尿病(type1diabetesmellitus,T1DM)的患病率占糖尿病总数的5

7、%-10%，影响了全球约2200万成人和40万儿童，且世界范围内的发病率以每年2%-3%的速度增长[2-3]。最新研究证实，75%的成人T1DM患者未能达到美国糖尿病学会(AmericanDiabetesAssociation,ADA)推荐的糖化血红蛋白(HbA1c)<7.0%的目标，仅有17%的青少年T1DM患者在接受胰岛素治疗后HbA1c达到7.5%[4]。而血糖控制不佳，不仅可以导致酮症酸中毒等急性并发症，还可以引起神经血管病变等慢性并发症，危及心、脑、肾、眼睛、足等，给患者及其家庭带来巨大损失。因此，积极预防和控制T1